All Articles

The nation's only public parking firm faces an insider offer, placing a special committee at the center of a high-stakes test for shareholder value.

With 13% revenue growth and a massive buyback, CarGurus' Q2 results show its AI-first strategy is reshaping the auto market and rewarding investors.

The software supply chain firm's Q2 results beat estimates, with cloud revenue soaring 53% as its security platform becomes essential for the AI era.

While Q2 results show a net loss, Bridger Aerospace secures record contracts and expands its tech, signaling a strategic shift for a new era of wildfire.

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

Rigetti Computing posts a $52.6M quarterly loss but secures major partnerships and potential government funding, betting big on its long-term quantum strategy.

Sprout Social's stellar Q2 profit beat isn't just a good quarter; it's a strategic overhaul. A look at its high-stakes bet on enterprise clients and AI.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

A new press release touts 'simplicity' as the future of digital entertainment. But for online gaming platform Mr Win77, are the real complexities hidden?

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

Outset Medical's Q2 results reveal a pivotal moment: a major HCA deal and stronger margins point to a new phase of sustainable growth in the dialysis market.

With a Q3 FDA submission for its novel epilepsy drug azetukalner imminent, Xenon leverages a massive cash runway to expand into neuropsychiatry and pain.

Stunning 120% revenue growth validates Senseonics' shift to in-house sales, but soaring costs and a widening net loss raise critical questions about its path to profitability.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

Doximity's Q1 results reveal a company at a crossroads, sacrificing near-term profits for AI dominance. Engagement is soaring, but financials are strained.

Clipper Realty's latest earnings reveal a stark divide. Record-breaking residential rents are being overshadowed by a major commercial property default.

A biotech firm has uncovered a self-perpetuating cycle that drives Alzheimer's from within the cell's mitochondria, and they've developed a drug to break it.

The strategic acquisition of The Mobility House North America by PowerFlex signals a major market consolidation, creating an end-to-end fleet solution powerhouse.

A Texas-based program offers a government-funded, no-cost path to six-figure IT jobs, providing a powerful new blueprint for closing the skills gap.